M a i n r e s u l t s 20 RCTs (2361 patients) met the selection criteria. Types of osteoporosis included postmenopausal osteoporosis (10 RCTs), idiopathic male osteoporosis (2 RCTs), and glucocorticoid-induced osteoporosis (1 RCT). 18 RCTs evaluated human PTH(l-34) administered subcutaneously. Dosages of PTH varied markedly among RCTs. Treatment duration ranged from 6 weeks to 3 years. Comparis...

Two dimensional thin layer chromatography on polyamide sheets is a useful method for identification of PTH-amino acids which have very close Rf-values. The solvent systems described here are particularly effective and have an edge over other solvent systems used for the separation of PTH-amino acids. The solvent systems provide a clear separation of all PTH-amono acids except lle / Leu in a...

The gene pth, encoding peptidyl-tRNA hydrolase (Pth), is essential for protein synthesis and viability of Escherichia coli. Two pth mutants have been studied in depth: a pth(Ts) mutant isolated as temperature sensitive and a pth(rap) mutant selected as nonpermissive for bacteriophage lambda vegetative growth. Here we show that each mutant protein is defective in a different way. The Pth(Ts) pro...

Daily application of parathyroid hormone (PTH 1-34) is used for treatment of osteoporosis. It was investigated whether orchiectomy-induced osteoporotic changes in spine can be ameliorated by every 48h administration of PTH in aged male rats. Eight-month-old male Sprague-Dawley rats were sham operated (n=24) or orchiectomized (Orx, n=36) and maintained untreated over 12 weeks. Thereafter, both t...

Parathyroid hormone (PTH) levels measured with the intact PTH assays are generally higher than those measured with the whole PTH assay; however, rare exceptions to this rule have been reported in patients with severe hyperparathyroidism associated with N-PTH overproduction. We report a haemodialysis patient with severe secondary hyperparathyroidism, in whom abnormally higher whole PTH levels th...

Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) target the kidney to cause a phosphaturia. FGF23 also acts on the parathyroid to decrease PTH expression, but in chronic kidney disease (CKD) there are high-serum PTH and FGF23 levels and resistance of the parathyroid to FGF23. We now report that PTH acts on bone to increase FGF23 expression and characterize the signal transducti...

• PTH levels determined using assays for iPTH and PTH(1-84) correlate closely. However, iPTH assays vary in their detection of C-terminal PTH fragments and values may differ between assays (Level lll evidence). PTH(1–84) assays that measure the full length polypeptide are reported to be more directly comparable. (Level lll evidence) For comparison of PTH values in multicentre clinical trials, t...

Osteocytes comprise a heterogenous population of terminally differentiated osteoblasts that direct bone remodeling in response to applied mechanical loading of bone. Increased osteocyte density accompanies the anabolic effect of PTH in vivo, whereas accelerated osteocyte death may be precipitated by estrogen deficiency or excess glucocorticoid exposure (conditions benefitted by intermittent PTH...

BACKGROUND A new commercially available (so-called second-generation) IRMA for parathyroid hormone (PTH) separately detects intact PTH and its N-truncated fragments; however, no studies have compared the first- and second-generation IRMAs for PTH in patients with primary hyperparathyroidism (PHPT) to assess their respective diagnostic accuracies. METHODS We concomitantly investigated 39 postm...

Intermittent PTH treatment increases cancellous bone mass in osteoporosis patients; however, it reveals diverse effects on cortical bone mass. Underlying molecular mechanisms for anabolic PTH actions are largely unknown. Because PTH regulates expression of osteopontin (OPN) in osteoblasts, OPN could be one of the targets of PTH in bone. Therefore, we examined the role of OPN in the PTH actions ...